Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


30.01.2017

3 Ann Thorac Surg
13 Anticancer Res
1 BMJ
1 Chest
1 Clin Cancer Res
3 Clin Lung Cancer
1 Eur J Cardiothorac Surg
1 Int J Cancer
1 Int J Oncol
5 J Clin Oncol
1 J Natl Cancer Inst
7 J Thorac Oncol
2 Lancet
1 Oncologist
3 PLoS One
1 Proc Natl Acad Sci U S A


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Thorac Surg

  1. SAMSON P, Crabtree TD, Robinson CG, Morgensztern D, et al
    Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer.
    Ann Thorac Surg. 2017 Jan 19. pii: S0003-4975(16)31305.
    PubMed     Text format     Abstract available

  2. RAJARAM R, Mohanty S, Bentrem DJ, Pavey ES, et al
    Nationwide Assessment of Robotic Lobectomy for Non-Small Cell Lung Cancer.
    Ann Thorac Surg. 2017 Jan 18. pii: S0003-4975(16)31377.
    PubMed     Text format     Abstract available

  3. ECKARDT J, Jakobsen E, Licht PB
    Subcarinal Lymph Nodes Should be Dissected in All Lobectomies for Non-Small Cell Lung Cancer-Regardless of Primary Tumor Location.
    Ann Thorac Surg. 2017 Jan 18. pii: S0003-4975(16)31378.
    PubMed     Text format     Abstract available


    Anticancer Res

  4. OKAMOTO T, Kitahara H, Shimamatsu S, Katsura M, et al
    Prognostic Impact of EGFR Driver Mutations on Postoperative Disease Recurrence in Lung Adenocarcinoma.
    Anticancer Res. 2016;36:3057-63.
    PubMed     Text format     Abstract available

  5. MATSUI T, Nagata N, Hirata K, Okazaki S, et al
    Bi-weekly Capecitabine-Oxaliplatin (XELOX) plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer -The PHOENiX Trial.
    Anticancer Res. 2016;36:3437-43.
    PubMed     Text format     Abstract available

  6. OISHI S, Kudaka W, Toita T, Ariga T, et al
    Prognostic Factors and Treatment Outcome for Patients with Stage IVB Cervical Cancer.
    Anticancer Res. 2016;36:3471-5.
    PubMed     Text format     Abstract available

  7. TOME Y, Yano S, Sugimoto N, Mii S, et al
    Use of alphav Integrin Linked to Green Fluorescent Protein in Osteosarcoma Cells and Confocal Microscopy to Image Molecular Dynamics During Lung Metastasis in Nude Mice.
    Anticancer Res. 2016;36:3811-6.
    PubMed     Text format     Abstract available

  8. MAYS AC, Feng X, Browne JD, Sullivan CA, et al
    Chemokine and Chemokine Receptor Profiles in Metastatic Salivary Adenoid Cystic Carcinoma.
    Anticancer Res. 2016;36:4013-8.
    PubMed     Text format     Abstract available

  9. URAMOTO H, Nakajima Y, Kinoshita H, Akiyama H, et al
    Equivalent Outcome of Patients with Locally Advanced NSCLC Treated with Salvage Surgery Compared to Induction Chemotherapy Followed by Surgical Resection.
    Anticancer Res. 2016;36:4243-7.
    PubMed     Text format     Abstract available


  10. Advances in Respiratory Cancerogenesis.
    Anticancer Res. 2016;36:4376.
    PubMed     Text format    

  11. TOYOKAWA G, Taguchi K, Edagawa M, Shimamatsu S, et al
    The Prognostic Impact of Jumonji Domain-containing 2B in Patients with Resected Lung Adenocarcinoma.
    Anticancer Res. 2016;36:4841-6.
    PubMed     Text format     Abstract available

  12. MATSUOKA Y, Yurugi Y, Takagi Y, Wakahara M, et al
    Prognostic Significance of Solid and Micropapillary Components in Invasive Lung Adenocarcinomas Measuring </=3 cm.
    Anticancer Res. 2016;36:4923-30.
    PubMed     Text format     Abstract available

  13. SHAVERDIAN N, Wang J, Levin-Epstein R, Schaue D, et al
    Pro-inflammatory State Portends Poor Outcomes with Stereotactic Radiosurgery for Brain Metastases.
    Anticancer Res. 2016;36:5333-5337.
    PubMed     Text format     Abstract available

  14. YURUGI Y, Wakahara M, Matsuoka Y, Sakabe T, et al
    Podoplanin Expression in Cancer-associated Fibroblasts Predicts Poor Prognosis in Patients with Squamous Cell Carcinoma of the Lung.
    Anticancer Res. 2017;37:207-213.
    PubMed     Text format     Abstract available

  15. FUJIYOSHI K, Yamamoto G, Takenoya T, Takahashi A, et al
    Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor.
    Anticancer Res. 2017;37:239-247.
    PubMed     Text format     Abstract available

  16. SUZAWA K, Shien K, Peng H, Sakaguchi M, et al
    Distant Bystander Effect of REIC/DKK3 Gene Therapy Through Immune System Stimulation in Thoracic Malignancies.
    Anticancer Res. 2017;37:301-307.
    PubMed     Text format     Abstract available


    BMJ

  17. MENDOZA N, Prasad P
    Pulmonary nodules in a man with a history of bone marrow transplantation.
    BMJ. 2016;353:i1805.
    PubMed     Text format    


    Chest

  18. MOLASSIOTIS A, Smith JA, Mazzone P, Blackhall F, et al
    Symptomatic Treatment of Cough Among Adult Patients With Lung Cancer: CHEST Guidelines and Expert Panel Report.
    Chest. 2017 Jan 17. pii: S0012-3692(17)30022-3. doi: 10.1016/j.chest.2016.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  19. BONANNO L, De Paoli A, Zulato E, Esposito G, et al
    LKB1 expression correlates with increased survival in advanced non-small cell lung cancer patients treated with chemotherapy and bevacizumab.
    Clin Cancer Res. 2017 Jan 24. pii: clincanres.2410.2016.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  20. SAKAKIBARA R, Inamura K, Tambo Y, Ninomiya H, et al
    EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer.
    Clin Lung Cancer. 2016 Dec 22. pii: S1525-7304(16)30378.
    PubMed     Text format     Abstract available

  21. LABBE C, Leung Y, Silva Lemes JG, Stewart E, et al
    Real-World EQ5D Health Utility Scores for Patients With Metastatic Lung Cancer by Molecular Alteration and Response to Therapy.
    Clin Lung Cancer. 2016 Dec 28. pii: S1525-7304(16)30391.
    PubMed     Text format     Abstract available

  22. WEISS J, Force RW, Pugmire BA, Peterson T, et al
    Comparative Effectiveness and Resource Usage in Patients Receiving First-line Taxane-based Chemotherapy for Stage IV Non-Small-cell Lung Cancer in a US Community Oncology Setting.
    Clin Lung Cancer. 2016 Dec 22. pii: S1525-7304(16)30384.
    PubMed     Text format     Abstract available


    Eur J Cardiothorac Surg

  23. MATSUNAGA T, Suzuki K, Takamochi K, Oh S, et al
    What is the radiological definition of part-solid tumour in lung cancer?dagger.
    Eur J Cardiothorac Surg. 2017 Jan 24. pii: ezw344. doi: 10.1093.
    PubMed     Text format     Abstract available


    Int J Cancer

  24. FEHRINGER G, Brenner DR, Zhang ZF, Lee YA, et al
    Alcohol and Lung Cancer Risk Among Never Smokers: A Pooled Analysis from the International Lung Cancer Consortium and the SYNERGY Study.
    Int J Cancer. 2017 Jan 24. doi: 10.1002/ijc.30618.
    PubMed     Text format     Abstract available


    Int J Oncol

  25. RUI Y, Peng WJ, Wang M, Wang Q, et al
    HIST1H3D: A promising therapeutic target for lung cancer.
    Int J Oncol. 2017 Jan 19. doi: 10.3892/ijo.2017.3856.
    PubMed     Text format     Abstract available


    J Clin Oncol

  26. MAGNUSON WJ, Lester-Coll NH, Wu AJ, Yang TJ, et al
    Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naive Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
    J Clin Oncol. 2017 Jan 23:JCO2016697144. doi: 10.1200/JCO.2016.69.7144.
    PubMed     Text format     Abstract available

  27. WANG K, Eblan MJ, Deal AM, Lipner M, et al
    Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy.
    J Clin Oncol. 2017 Jan 23:JCO2016700229. doi: 10.1200/JCO.2016.70.0229.
    PubMed     Text format     Abstract available

  28. MARCUS MW, Field JK
    Is Bootstrapping Sufficient for Validating a Risk Model for Selection of Participants for a Lung Cancer Screening Program?
    J Clin Oncol. 2017 Jan 23:JCO2016713214. doi: 10.1200/JCO.2016.71.3214.
    PubMed     Text format    

  29. SIMONE CB 2ND
    New Era in Radiation Oncology for Lung Cancer: Recognizing the Importance of Cardiac Irradiation.
    J Clin Oncol. 2017 Jan 23:JCO2016715581. doi: 10.1200/JCO.2016.71.5581.
    PubMed     Text format    

  30. ZHOU L, Deng L, Lu Y
    Epidermal Growth Factor Receptor Mutations in Non-Small-Cell Lung Cancer With Brain Metastasis: Can Up-Front Radiation Therapy Be Deferred or Withheld?
    J Clin Oncol. 2017 Jan 23:JCO2016715706. doi: 10.1200/JCO.2016.71.5706.
    PubMed     Text format    


    J Natl Cancer Inst

  31. BROWER V
    Researchers Identify High-Risk Subtype of Stage I Lung Cancer.
    J Natl Cancer Inst. 2017;109:3-4.
    PubMed     Text format    


    J Thorac Oncol

  32. LE PECHOUX C
    Prophylactic Cranial Irradiation or No Prophylactic Cranial Irradiation after Adjuvant Chemotherapy in Resected Small Cell Lung Cancer?
    J Thorac Oncol. 2017;12:173-175.
    PubMed     Text format    

  33. DAVID EA, Daly ME, Li CS, Chiu CL, et al
    Increasing Rates of No Treatment in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Propensity-Matched Analysis.
    J Thorac Oncol. 2017 Jan 18. pii: S1556-0864(16)33476.
    PubMed     Text format     Abstract available

  34. ZHU M, Geng L, Shen W, Wang Y, et al
    Exome-wide association study identifies low-frequency coding variants in 2p23.2 and 7p11.2 associated with survival of non-small cell lung cancer patients.
    J Thorac Oncol. 2017 Jan 16. pii: S1556-0864(17)30013.
    PubMed     Text format     Abstract available

  35. VELCHETI V, Thawani R, Khunger M, Mukhopadhyay S, et al
    FRMD4A/RET: A Novel RET Oncogenic Fusion Variant in Non-Small Cell Lung Carcinoma.
    J Thorac Oncol. 2017;12:e15-e16.
    PubMed     Text format    

  36. VELCHETI V, Khunger M, Abazeed ME
    Novel EGFR Exon 18 (G721R) Mutation in a Patient with Non-Small Cell Lung Carcinoma with Lack of Response to Afatinib.
    J Thorac Oncol. 2017;12:e16-e18.
    PubMed     Text format    

  37. SAWABATA N
    Cluster Circulating Tumor Cell Is Crucial in Surgically Resected Lung Cancer.
    J Thorac Oncol. 2017;12:e18-e19.
    PubMed     Text format    

  38. DAI J, Liu M, Swensen SJ, Stoddard SM, et al
    Regional Emphysema Score Predicting Overall Survival, Quality of Life and Pulmonary Function Recovery in Early-stage Lung Cancer Patients.
    J Thorac Oncol. 2017 Jan 23. pii: S1556-0864(17)30040.
    PubMed     Text format     Abstract available


    Lancet

  39. SOLOMON B
    First-line treatment options for ALK-rearranged lung cancer.
    Lancet. 2017 Jan 23. pii: S0140-6736(17)30124.
    PubMed     Text format    

  40. SORIA JC, Tan DS, Chiari R, Wu YL, et al
    First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
    Lancet. 2017 Jan 23. pii: S0140-6736(17)30123.
    PubMed     Text format     Abstract available


    Oncologist

  41. DONG ZY, Zhai HR, Hou QY, Su J, et al
    Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer.
    Oncologist. 2017;22:61-69.
    PubMed     Text format     Abstract available


    PLoS One

  42. XIAO L, Liu N, Zhang G, Zhang H, et al
    Late-Course Adaptive Adjustment Based on Metabolic Tumor Volume Changes during Radiotherapy May Reduce Radiation Toxicity in Patients with Non-Small Cell Lung Cancer.
    PLoS One. 2017;12:e0170901.
    PubMed     Text format     Abstract available

  43. LOKK K, Vooder T, Kolde R, Valk K, et al
    Correction: Methylation Markers of Early-Stage Non-Small Cell Lung Cancer.
    PLoS One. 2017;12:e0170833.
    PubMed     Text format     Abstract available

  44. NATTENMULLER J, Wochner R, Muley T, Steins M, et al
    Prognostic Impact of CT-Quantified Muscle and Fat Distribution before and after First-Line-Chemotherapy in Lung Cancer Patients.
    PLoS One. 2017;12:e0169136.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  45. SHRIVASTAVA M, Lou S, Zelenyuk A, Easter RC, et al
    Global long-range transport and lung cancer risk from polycyclic aromatic hydrocarbons shielded by coatings of organic aerosol.
    Proc Natl Acad Sci U S A. 2017 Jan 23. pii: 201618475.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: